Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharvaris N.V.

22.99
-0.8100-3.40%
Volume:158.23K
Turnover:3.63M
Market Cap:1.25B
PE:-7.56
High:24.41
Open:23.78
Low:22.05
Close:23.80
Loading ...

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Pharvaris (PHVS)

TIPRANKS
·
Yesterday

Bank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)

TIPRANKS
·
11 Jul

Pharvaris Expects to Release Topline Data From Phase 3 Hereditary Angioedema Study in Q4

MT Newswires Live
·
10 Jul

Pharvaris to report topline Phase 3 results of deucrictibant in Q4

TIPRANKS
·
10 Jul

BRIEF-Pharvaris NV - Expects Rapide-3 Data Announcement In Q4 2025

Reuters
·
10 Jul

Pharvaris NV to Announce Third Quarter 2025 Financial Results

Reuters
·
10 Jul

Pharvaris Nv - Expects Rapide-3 Data Announcement in Q4 2025

THOMSON REUTERS
·
10 Jul

Pharvaris Nv - Plans Nda Submission to FDA in H1 2026

THOMSON REUTERS
·
10 Jul

Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Simply Wall St.
·
05 Jul

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and Pharvaris (PHVS)

TIPRANKS
·
30 Jun

Pharvaris Announces Key Resolutions from Annual General Meeting

TIPRANKS
·
28 Jun

Pharvaris NV Conducted Annual General Meeting of Shareholders

Reuters
·
28 Jun

Pharvaris NV to Present Promising Clinical Trial Data on Oral Deucrictibant for Hereditary Angioedema at 2025 US HAEA National Summit

Reuters
·
27 Jun

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of Hae to Be Presented at the 2025 US Haea National Summit

THOMSON REUTERS
·
27 Jun

Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025

Reuters
·
16 Jun

Pharvaris initiated with a Buy at Guggenheim on HAE potential

TIPRANKS
·
11 Jun

Guggenheim Initiates Coverage on Pharvaris With Buy Rating, $32 Price Target

MT Newswires Live
·
11 Jun

Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials

TIPRANKS
·
10 Jun

Press Release: Pharvaris Announces Annual Meeting of Shareholders

Dow Jones
·
10 Jun

Pharvaris NV Publishes 2024 Annual Report

Reuters
·
10 Jun